Effects of Erythropoietin on the Lipid Metabolism in Pre-dialysis Patients
YUAN Min,ZOU Jianzhou,Zhang Xiaoyan,Ding Xiaoqiang
DOI: https://doi.org/10.3969/j.issn.1008-6358.2009.06.032
2009-01-01
Abstract:Objective:To investigate the effects of erythropoietin (EPO) administration on lipid metabolism in pre-dialysis patients with chronic kidney disease(CKD).Methods:Totally 120 pre-dialysis patients with CKD were enrolled.Among which,71 patients were treated with EPO,subcutaneous injection,initially 10000 U once a week and later once every two weeks after hemoglobin ≥110 g·L-1.The remaining 49 patients who did not receive EPO treatment were taken as control group.Folic acid and iron were suppled orally in both groups,but lipid-lowering drugs were not suppled.In the observation period of 1 year,renal function,electrolyte,blood routine examination,blood pressure were measured every month,serum level of TC,TG,LDL-C,HDL-C,LP-a were measured every three months.Results:At the end of the study of 12 months,serum levels of TC,LDL-C,Lp(a) significantly decreased from 5.53±0.43 mmol·L-1,3.81±0.81 mmol·L-1,249 ±80.1 mg·L-1 to 4.78±0.56 mmol·L-1,3.09±0.93 mmol·L-1,217±92.5mg·L-1 respectively in EPO treatment group(P<0.05).TG only decreased sligthly(P>0.05).In control group,TC,TG,LDL-C,Lp (a) decreased in varying degrees,but only TC decreased significantly(5.67±0.76 vs.5.27±0.72 mmol·L-1,P<0.05).TC decreased more significantly in the treatment group compared with the control group (P<0.05).However,serum HDL-C levels significantly increased in treatment group (1.31±0.25vs.1.82±0.29 mmol·L-1,P< 0.05),whereas they remained unchanged in control group.The change was also significantly differant between two groups.Conclusions:Our results indicate that EPO treatment could improve the lipid metabolism in pre-dialysis patients with CKD.